Cargando…
Recurrent Glioblastoma: Where we stand
Current first-line treatment regimens combine surgical resection and chemoradiation for Glioblastoma that provides a slight increase in overall survival. Age on its own should not be used as an exclusion criterion of glioblastoma multiforme (GBM) treatment, but performance should be factored heavily...
Autores principales: | Roy, Sanjoy, Lahiri, Debarshi, Maji, Tapas, Biswas, Jaydip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772393/ https://www.ncbi.nlm.nih.gov/pubmed/26981507 http://dx.doi.org/10.4103/2278-330X.175953 |
Ejemplares similares
-
Immunomodulated anterior chemotherapy followed by concurrent chemoradiotherapy in locally advanced tongue cancer: An Institutional experience
por: Chhatui, Bappaditya, et al.
Publicado: (2015) -
Addition of gemcitabine to standard therapy in locally advanced cervical cancer: A randomized comparative study
por: Roy, Sanjoy, et al.
Publicado: (2011) -
Tumor bed boost in breast cancer: Brachytherapy versus electron beam
por: Roy, Sanjoy, et al.
Publicado: (2013) -
Bilateral angiosarcoma of breast in a young lady
por: Roy, Sanjoy, et al.
Publicado: (2011) -
Immune-checkpoint inhibitors for glioblastoma: what have we learned?
por: Omuro, Antonio
Publicado: (2022)